NCT06292052Completed
Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness
Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis
Source: ClinicalTrials.gov · Last updated 14 May 2024
Brief summary (registry, in English)
The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 209 (actual)
- First submitted
- 23 Feb 2024
- Start date
- 1 Jan 2017
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Lung cancer
- NCT number
- NCT06292052
What you commit to
- Study type: Observational
- Participants enrolled: 209
- From 1 Jan 2017 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- using PD-1/L1 inhibitors in the phase of clinical trials
- the agents of neoadjuvant therapy including angiogenesis inhibitors
- having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery
Who the study is looking for
- pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy
- clinically staged as T1-4N0-2M0
- having undergo neoadjuvant chemoimmunotherapy
- the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors
- having undergo surgery with lymph nodes (LNs) dissection
- having postoperative pathology reports with evaluation of primary tumor and LNs response
- having accessible pretreatment and preoperative radiology examinations imaging or reports
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.